GSK, Teva Face Antitrust Class Action Over Lamictal Deal

Law360, New York (February 23, 2012, 7:32 PM EST) -- A drug distributor lodged a putative antitrust class action against GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. in New Jersey federal court Wednesday, accusing the companies of conspiring to keep a generic epilepsy drug off the market in order to maximize profits.

Louisiana Wholesale Drug Co. Inc. filed the suit on behalf of all those who purchased Lamictal-brand lamotrigine tablets since February 2008, alleging that Teva put the brakes on a patent challenge to Lamictal in 2005 in order to strike a deal with GSK that...
To view the full article, register now.